RxDoctor Payments Data

Steven Konicki, DO

Family Medicine · Kalamazoo, MINPI 1164512034

Payments from drug & device makers

$2,074in general payments, 2019–2025

Across 87 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$793
  • AbbVie$201
  • Abbott$197
  • Boehringer Ingelheim$159
  • Merck$109
  • Pfizer$102
  • plus $512 from 10 others

What the payments were for

  • Food & beverage$2,06299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,074 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$76,840
Medicare patients
269
Services billed
1,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$151,191
OzempicSemaglutide85$144,305
JardianceEmpagliflozin119$126,596
XareltoRivaroxaban57$88,312
MounjaroTirzepatide53$72,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$61,846
TrulicityDulaglutide50$50,938
EntrestoSacubitril/Valsartan22$26,455
Spiriva RespimatTiotropium Bromide27$21,739
LinzessLinaclotide22$17,320
MyrbetriqMirabegron22$14,195
Atorvastatin Calcium699$11,194
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$10,523
SymbicortBudesonide/Formoterol Fumarate12$6,617
OxycontinOxycodone Hcl12$5,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$151,191141 claims
Boehringer IngelheimJardiance, Spiriva Respimat$159$148,334146 claims
Novo NordiskOzempic$793$144,30585 claims
Lilly USA, LLCMounjaro, Trulicity$101$123,527103 claims
Johnson & JohnsonXarelto$68$88,31257 claims
GSKTrelegy Ellipta$59$61,84650 claims
AbbVieLinzess$201$17,32022 claims
AstraZenecaSymbicort$46$6,61712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →